19 related articles for article (PubMed ID: 9405728)
1. Physical activity may be a potent regulator of bone turnover biomarkers in healthy girls during preadolescence.
Kambas A; Leontsini D; Avloniti A; Chatzinikolaou A; Stampoulis T; Makris K; Draganidis D; Jamurtas AZ; Tournis S; Fatouros IG
J Bone Miner Metab; 2017 Nov; 35(6):598-607. PubMed ID: 27838794
[TBL] [Abstract][Full Text] [Related]
2. Integrated pharmacometrics and systems pharmacology model-based analyses to guide GnRH receptor modulator development for management of endometriosis.
Riggs MM; Bennetts M; van der Graaf PH; Martin SW
CPT Pharmacometrics Syst Pharmacol; 2012 Oct; 1(10):e11. PubMed ID: 23887363
[TBL] [Abstract][Full Text] [Related]
3. Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density.
Sagsveen M; Farmer JE; Prentice A; Breeze A
Cochrane Database Syst Rev; 2003; 2003(4):CD001297. PubMed ID: 14583930
[TBL] [Abstract][Full Text] [Related]
4. Intermittent Etidronate partially prevents bone loss in hirsute hyperandrogenic women treated with GnRH agonist.
Zamberlan N; Castello R; Gatti D; Rossini M; Braga V; Fracassi E; Adami S
Osteoporos Int; 1997; 7(2):133-7. PubMed ID: 9166393
[TBL] [Abstract][Full Text] [Related]
5. Effect of long-term growth-hormone substitution therapy on bone mineral density and parameters of bone metabolism in adult patients with growth hormone deficiency.
Kotzmann H; Riedl M; Bernecker P; Clodi M; Kainberger F; Kaider A; Woloszczuk W; Luger A
Calcif Tissue Int; 1998 Jan; 62(1):40-6. PubMed ID: 9405732
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of bone density in girls with precocious and early puberty during treatment with GnRH agonist.
Assa A; Weiss M; Aharoni D; Mor A; Rachmiel M; Bistritzer T
J Pediatr Endocrinol Metab; 2011; 24(7-8):505-10. PubMed ID: 21932589
[TBL] [Abstract][Full Text] [Related]
7. Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study.
Morabito N; Crisafulli A; Vergara C; Gaudio A; Lasco A; Frisina N; D'Anna R; Corrado F; Pizzoleo MA; Cincotta M; Altavilla D; Ientile R; Squadrito F
J Bone Miner Res; 2002 Oct; 17(10):1904-12. PubMed ID: 12369794
[TBL] [Abstract][Full Text] [Related]
8. The impact of subcutaneous oestradiol implants on biochemical markers of bone turnover and bone mineral density in postmenopausal women.
Pereda CA; Hannon RA; Naylor KE; Eastell R
BJOG; 2002 Jul; 109(7):812-20. PubMed ID: 12135219
[TBL] [Abstract][Full Text] [Related]
9. Biochemical markers as predictors of bone mineral density changes after GnRH agonist treatment.
Borderie D; Cherruau B; Dougados M; Ekindjian OG; Roux C
Calcif Tissue Int; 1998 Jan; 62(1):21-5. PubMed ID: 9405728
[TBL] [Abstract][Full Text] [Related]
10. Molecular markers of bone turnover: biochemical, technical and analytical aspects.
Seibel MJ
Osteoporos Int; 2000; 11 Suppl 6():S18-29. PubMed ID: 11193236
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
